☰

Weichung J. Shih - Publications

Affiliations: 
Rutgers University, New Brunswick, New Brunswick, NJ, United States 
Area:
Biostatistics Biology
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology. 9: 1483. PMID 31998643 DOI: 10.3389/Fonc.2019.01483  0.324
2019 Portal DE, Weiss RE, Wojtowicz M, Mansour A, Monken C, Mehnert JM, Aisner JA, Kane M, Nishioka J, Aisner S, Peters S, Stein MN, Kim IY, Mayer TM, Shih W, et al. Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. Cancer Gene Therapy. PMID 31222182 DOI: 10.1038/S41417-019-0112-Z  0.315
2018 Song M, Kumaran MN, Gounder M, Gibbon DG, Nieves-Neira W, Vaidya A, Hellmann M, Kane MP, Buckley B, Shih W, Caffrey PB, Frenkel GD, Rodriguez-Rodriguez L. Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecologic Oncology. PMID 30068487 DOI: 10.1016/J.Ygyno.2018.07.001  0.354
2018 Dinizo M, Shih W, Kwon YS, Eun D, Reese A, Giusto L, Trabulsi EJ, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu SD, Eggener S, Kim IY. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget. 9: 21359-21365. PMID 29765545 DOI: 10.18632/Oncotarget.25103  0.362
2018 Mehnert JM, Silk AW, Wen Y, Lee JH, Dudek L, Jeong BS, Li J, Schenkel JM, Sadimin E, Kane M, Lin H, Shih WJ, Zloza A, Chen S, Goydos JS. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma. Pigment Cell & Melanoma Research. PMID 29453787 DOI: 10.1111/Pcmr.12694  0.351
2018 Silk AW, Berman R, Coric V, Ruggiero L, Reitz AB, Shih W, Kane MP, Mehnert JM, Pelletier JC, Zloza A, Goydos JS. A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies. Journal of Clinical Oncology. 36: TPS80-TPS80. DOI: 10.1200/Jco.2018.36.5_Suppl.Tps80  0.346
2017 Shih WJ, Lin Y. On study designs and hypotheses for clinical trials with predictive biomarkers. Contemporary Clinical Trials. PMID 28838813 DOI: 10.1016/J.Cct.2017.08.014  0.305
2015 Lu-Yao GL, Kim S, Moore DF, Shih W, Lin Y, DiPaola RS, Shen S, Zietman A, Yao SL. Primary radiotherapy vs conservative management for localized prostate cancer-a population-based study. Prostate Cancer and Prostatic Diseases. PMID 26101187 DOI: 10.1038/Pcan.2015.30  0.38
2015 Hirshfield KM, Lu S, Wong S, Tan A, Kirstein L, Kearney T, Shih W, Ganesan S, Toppmeyer DL. Abstract P3-10-09: A Phase II trial of doxil, carboplatin and bevacizumab in metastatic triple negative breast cancer and molecular correlates of response Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-10-09  0.355
2015 Dinizo M, Shih W, Salmasi A, Faiena I, Modi P, Han M, Partin AW, Eun D, Reese A, Llukani E, Giosto L, Wessel S, Trabulsi E, Lallas C, Yuh B, et al. MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1698  0.342
2014 Song M, DiPaola RS, Cracchiolo BM, Gibbon DG, Hellmann M, Nieves-Neira W, Vaidya A, Wagreich AR, Shih WJ, Rodriguez-Rodriguez L. Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 24: 1636-41. PMID 25304678 DOI: 10.1097/Igc.0000000000000258  0.369
2014 Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. Jama Internal Medicine. 174: 1460-7. PMID 25023796 DOI: 10.1001/Jamainternmed.2014.3028  0.391
2014 Fang F, Lin Y, Shih WJ, Li Y, Yang J, Zhang X. Methods of designing two-stage winner trials with survival outcomes. Statistics in Medicine. 33: 1539-63. PMID 24347247 DOI: 10.1002/Sim.6070  0.326
2014 Tan AR, Wong ST, Warren RD, Eng-Wong J, Liu MC, Zelnak AB, Lin Y, Shih W, Ganesan S, Grana G, Isaacs C, Toppmeyer D. Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 32: 531-531. DOI: 10.1200/Jco.2014.32.15_Suppl.531  0.354
2014 Lu-Yao GL, Albertsen PC, Moore D, Shih W, Lin Y, DiPaola RS, Yao S. 15-year survival outcomes following primary androgen deprivation therapy for localized prostate cancer. Journal of Clinical Oncology. 32: 5033-5033. DOI: 10.1200/Jco.2014.32.15_Suppl.5033  0.405
2013 Moore D, Lin Y, Demissie K, Shih W, Albertsen PC, DiPaola RS, Yao SL. Racial differences in survival outcomes among men with localized prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 98. PMID 28137152 DOI: 10.1200/Jco.2013.31.6_Suppl.98  0.381
2012 Goodin S, Stein MN, Shih W, Lu SE, Zheng X, Anand M, Jeyamohan C, Mayer TM, Somer RA, Heath E, Conney A, DiPaola RS. A phase II study of atorvastatin and celecoxib in patients with rising PSA following local therapy for prostate cancer (PC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 89. PMID 27968290 DOI: 10.1200/Jco.2012.30.5_Suppl.89  0.375
2012 Dong G, Shih WJ, Moore D, Quan H, Marcella S. A Bayesian-frequentist two-stage single-arm phase II clinical trial design. Statistics in Medicine. 31: 2055-67. PMID 22415966 DOI: 10.1002/Sim.5330  0.469
2012 Lu-Yao G, Kim S, Moore D, Shih W, Lin Y, DiPaola R, Zietman A, Li H, Shao Y, Yao S. 685 OUTCOMES OF RADIOTHERAPY AMONG MEN WITH LOW-RISK LOCALIZED PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.768  0.356
2012 Lu-Yao G, Moore D, Shih W, Lin Y, DiPaola R, Li H, Albertsen P, Yao S. 1820 CLINICAL OUTCOMES FOLLOWING PRIMARY ANDROGEN DEPRIVATION THERAPY AMONG MEN WITH LOCALIZED PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1886  0.378
2012 Kim S, Shih WJ, Lu-Yao GL. Reply to Carl J. Rossi, Jr.'s Letter to the editor re: Sung Kim, Shunhua Shen, Dirk F. Moore, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol 2011;60:908-16 European Urology. 61. DOI: 10.1016/J.Eururo.2012.01.054  0.316
2011 Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, Karantza V. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Molecular Cancer Therapeutics. 10: 1509-19. PMID 21680752 DOI: 10.1158/1535-7163.Mct-10-0944  0.341
2011 Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1335-41. PMID 21357791 DOI: 10.1200/Jco.2010.31.2330  0.373
2010 Mehnert JM, Lee JH, Shirk J, Bhavsar D, Anosike O, Chan JL, Shih W, Chen S, Goydos JS. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in metastatic melanoma. Journal of Clinical Oncology. 28: TPS309-TPS309. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps309  0.337
2009 Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL. Outcomes of localized prostate cancer following conservative management. Jama. 302: 1202-9. PMID 19755699 DOI: 10.1001/Jama.2009.1348  0.395
2009 Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, Dipaola RS, Lu-Yao GL. Contemporary risk profile of prostate cancer in the United States. Journal of the National Cancer Institute. 101: 1280-3. PMID 19713548 DOI: 10.1093/Jnci/Djp262  0.379
2009 Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A, Kempf J, Shih WJ, Chen S, Goydos JS. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3896-902. PMID 19458050 DOI: 10.1158/1078-0432.Ccr-08-3303  0.33
2009 Lu-Yao G, Albertsen P, Shih W, Yao SL. Failure to Report Financial Disclosure Information Jama. 301: 35-36. PMID 19126808 DOI: 10.1001/Jama.2008.905  0.399
2009 Lu-Yao GL, Shih W, Yao SL. Primary Androgen Deprivation Therapy in Men With Prostate Cancer—Reply Jama. 301: 35-35. DOI: 10.1001/Jama.2008.904  0.395
2008 Sovak MA, Guensch L, Joyce P, Lutzker SG, Schwartz S, Shih WJ, Zheng L, Aisner J. A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)-Final report. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 19105. PMID 27947537 DOI: 10.1200/Jco.2008.26.15_Suppl.19105  0.329
2008 Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL. Survival following primary androgen deprivation therapy among men with localized prostate cancer. Jama. 300: 173-81. PMID 18612114 DOI: 10.1001/Jama.300.2.173  0.399
2008 Saraiya B, Gounder M, Dutta J, Saleem A, Collazo C, Zimmerman L, Nazar A, Gharibo M, Schaar D, Lin Y, Shih W, Aisner J, Strair RK, Rubin EH. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anti-Cancer Drugs. 19: 411-20. PMID 18454051 DOI: 10.1097/Cad.0B013E3282F5218B  0.301
2005 Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. The Prostate. 62: 115-22. PMID 15389797 DOI: 10.1002/Pros.20130  0.381
2004 He W, Shih WJ. Use of joint models to assess treatment effects on disease markers and clinical events: the Proscar Long-Term Efficacy and Safety Study (PLESS). Clinical Trials (London, England). 1: 362-7. PMID 16279274 DOI: 10.1191/1740774504Cn033Oa  0.478
2001 DiPaola RS, Chenven ES, Shih WJ, Lin Y, Amenta P, Goodin S, Shumate A, Capanna T, Cardiella M, Cummings KB, Aisner J, Todd MB. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. Cancer. 92: 2065-71. PMID 11596021 DOI: 10.1002/1097-0142(20011015)92:8<2065::Aid-Cncr1546>3.0.Co;2-K  0.35
Show low-probability matches.